The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) has dropped by -4.91 compared to previous close of 3.26. Despite this, the company has seen a fall of -12.43% in its stock price over the last five trading days. globenewswire.com reported 2024-12-03 that WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris’ Board of Directors (the “Committee”) granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris’ new President and Chief Operating Officer, nonstatutory stock options to purchase 375,000 shares of its common stock and 107,000 restricted stock units under the 2024 Inducement Plan.
Is It Worth Investing in Aclaris Therapeutics Inc (NASDAQ: ACRS) Right Now?
Moreover, the 36-month beta value for ACRS is 0.47. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACRS is 59.91M and currently, short sellers hold a 4.14% of that float. On December 18, 2024, ACRS’s average trading volume was 2.30M shares.
ACRS’s Market Performance
The stock of Aclaris Therapeutics Inc (ACRS) has seen a -12.43% decrease in the past week, with a -1.27% drop in the past month, and a 156.20% gain in the past quarter. The volatility ratio for the week is 9.36%, and the volatility levels for the past 30 days are at 13.74% for ACRS. The simple moving average for the past 20 days is -16.05% for ACRS’s stock, with a 99.46% simple moving average for the past 200 days.
Analysts’ Opinion of ACRS
Leerink Partners, on the other hand, stated in their research note that they expect to see ACRS reach a price target of $7, previously predicting the price at $2. The rating they have provided for ACRS stocks is “Outperform” according to the report published on November 19th, 2024.
Jefferies gave a rating of “Buy” to ACRS, setting the target price at $7 in the report published on November 19th of the current year.
ACRS Trading at 18.92% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.04% of loss for the given period.
Volatility was left at 13.74%, however, over the last 30 days, the volatility rate increased by 9.36%, as shares sank -32.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +166.61% upper at present.
During the last 5 trading sessions, ACRS fell by -12.64%, which changed the moving average for the period of 200-days by +143.52% in comparison to the 20-day moving average, which settled at $3.69. In addition, Aclaris Therapeutics Inc saw 195.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Mehra Anand, who purchase 666,666 shares at the price of $2.25 back on Nov 19 ’24. After this action, Mehra Anand now owns 710,030 shares of Aclaris Therapeutics Inc, valued at $1,499,998 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 206,025 shares at $1.24 during a trade that took place back on Aug 05 ’24, which means that Leonard Braden Michael is holding 14,250,000 shares at $256,357 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.54 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -1.37. The total capital return value is set at -0.25. Equity return is now at value -25.83, with -18.47 for asset returns.
Currently, EBITDA for the company is -117.56 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 6.55. The receivables turnover for the company is 78.95for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
To wrap up, the performance of Aclaris Therapeutics Inc (ACRS) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
